Qing Hai Zhao
Corporate Officer/Principal at ADAGENE INC.
Qing Hai Zhao active positions
| Companies | Position | Start | End |
|---|---|---|---|
| ADAGENE INC. | Corporate Officer/Principal | 2020-09-30 | - |
Career history of Qing Hai Zhao
Former positions of Qing Hai Zhao
| Companies | Position | Start | End |
|---|---|---|---|
| FORTY SEVEN, INC. | Corporate Officer/Principal | 2016-12-31 | 2020-09-30 |
| ANAPTYSBIO, INC. | Corporate Officer/Principal | 2015-12-31 | 2016-12-31 |
| NGM BIOPHARMACEUTICALS, INC. | Director/Board Member | 2013-12-31 | 2015-12-31 |
| Corporate Officer/Principal | 2013-12-31 | 2015-12-31 |
Training of Qing Hai Zhao
| East China University of Science & Technology | Undergraduate Degree |
| University of Uppsala | Doctorate Degree |
| Zhongshan Hospital Fudan University | Graduate Degree |
Statistics
International
| China | 4 |
| United States | 4 |
| Sweden | 2 |
Operational
| Corporate Officer/Principal | 4 |
| Director/Board Member | 1 |
| Undergraduate Degree | 1 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 4 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 3 |
|---|---|
| ADAGENE INC. | Health Technology |
| ANAPTYSBIO, INC. | Health Technology |
| NGM BIOPHARMACEUTICALS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Forty Seven, Inc.
 Forty Seven, Inc. Pharmaceuticals: MajorHealth Technology Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA. | Health Technology |
- Stock Market
- Insiders
- Qing Hai Zhao
- Experience
